Manabu Date
6 Papers
44 Citations
Manabu Date is an academic researcher. The author has contributed to research in topics: Cancer & Metastatic breast cancer. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Factors responsible for long-term survival in metastatic breast cancer.
Keiichi Kontani,Shinichiro Hashimoto,Chisa Murazawa,Shoko Norimura,Hiroaki Tanaka,Masahiro Ohtani,Naomi Fujiwara-Honjo,Manabu Date,Koji Teramoto,Hitoshi Houchi,Hiroyasu Yokomise +10 more
TL;DR: Patients with luminal-type MBC who benefit at least once from chemotherapy including metronomic regimens, or patients who continued to receive the most effective regimen for more than two years can be expected to have long-term survival after diagnosis of MBC, regardless of the number of chemotherapeutic regimens they had received.
Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.
Keiichi Kontani,Shinichiro Hashimoto,Chisa Murazawa,Shoko Norimura,Hiroaki Tanaka,Masahiro Ohtani,Naomi Fujiwara-Honjo,Manabu Date,Hitoshi Houchi,Hiroyasu Yokomise +9 more
TL;DR: It is suggested that metronomic chemotherapy is useful for palliative care and also improved clinical outcomes as a regimen for which long-term administration may be expected.
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Keiichi Kontani,Noriyuki Kuroda,Shinichiro Hashimoto,Chisa Murazawa,Shoko Norimura,Hiroaki Tanaka,Masahiro Ohtani,Naomi Fujiwara-Honjo,Yoshio Kushida,Manabu Date,Reiji Haba,Hitoshi Houchi,Akira Yamauchi,Hiroyasu Yokomise +13 more
TL;DR: The results suggest that HER2ECD is a useful biomarker not only for detecting breast cancer recurrence but also for predicting tumor responses to trastuzumab.
9
Indication of metronomic chemotherapy for metastatic breast cancer: clinical outcomes and responsive subtypes
Keiichi Kontani,Shinichiro Hashimoto,Chisa Murazawa,Shoko Norimura,Hiroaki Tanaka,Masahiro Ohtani,Naomi Fujiwara-Honjo,Manabu Date,Koji Teramoto,Hitoshi Houchi,Hiroyasu Yokomise +10 more
TL;DR: In conclusion, metronomic chemotherapy is a viable option for luminal-type MBC in terms of effectiveness and minimal toxicity, regardless of metastatic sites or prior treatment, however, an alternative treatment is required for TN cancer.
Prolonged Survival in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressed Metastatic Breast Cancer after Targeted Therapy is Dominantly Contributed by Luminal-Human Epidermal Growth Factor Receptor-2 Population
Keiichi Kontani,Kana Kuraishi,Shinichiro Hashimoto,Shoko Norimura,Nozomi Hashimoto,Masahiro Ohtani,Naomi Fujiwara-Honjo,Manabu Date,Koji Teramoto,Hiroyasu Yokomise +9 more
2